Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
24 09 2021
Historique:
received: 05 06 2021
revised: 05 08 2021
accepted: 10 08 2021
pubmed: 8 9 2021
medline: 24 9 2021
entrez: 7 9 2021
Statut: ppublish

Résumé

Rapid assessment of COVID-19 vaccine safety during pregnancy is urgently needed. We conducted a rapid systematic review, to evaluate the safety of COVID-19 vaccines selected by the COVID-19 Vaccines Global Access-Maternal Immunization Working Group in August 2020, including their components and their technological platforms used in other vaccines for pregnant persons. We searched literature databases, COVID-19 vaccine pregnancy registries, and explored reference lists from the inception date to February 2021 without language restriction. Pairs of reviewers independently selected studies through COVIDENCE, and performed the data extraction and the risk of bias assessment. Discrepancies were resolved by consensus. Registered on PROSPERO (CRD42021234185). We retrieved 6757 records and 12 COVID-19 pregnancy registries from the search strategy; 38 clinical and non-clinical studies (involving 2,398,855 pregnant persons and 56 pregnant animals) were included. Most studies (89%) were conducted in high-income countries and were cohort studies (57%). Most studies (76%) compared vaccine exposures with no exposure during the three trimesters of pregnancy. The most frequent exposure was to AS03 adjuvant, in the context of A/H1N1 pandemic influenza vaccines, (n = 24) and aluminum-based adjuvants (n = 11). Only one study reported exposure to messenger RNA in lipid nanoparticles COVID-19 vaccines. Except for one preliminary report about A/H1N1 influenza vaccination (adjuvant AS03), corrected by the authors in a more thorough analysis, all studies concluded that there were no safety concerns. This rapid review found no evidence of pregnancy-associated safety concerns of COVID-19 vaccines or of their components or platforms when used in other vaccines. However, the need for further data on several vaccine platforms and components is warranted, given their novelty. Our findings support current WHO guidelines recommending that pregnant persons may consider receiving COVID-19 vaccines, particularly if they are at high risk of exposure or have comorbidities that enhance the risk of severe disease.

Sections du résumé

BACKGROUND
Rapid assessment of COVID-19 vaccine safety during pregnancy is urgently needed.
METHODS
We conducted a rapid systematic review, to evaluate the safety of COVID-19 vaccines selected by the COVID-19 Vaccines Global Access-Maternal Immunization Working Group in August 2020, including their components and their technological platforms used in other vaccines for pregnant persons. We searched literature databases, COVID-19 vaccine pregnancy registries, and explored reference lists from the inception date to February 2021 without language restriction. Pairs of reviewers independently selected studies through COVIDENCE, and performed the data extraction and the risk of bias assessment. Discrepancies were resolved by consensus. Registered on PROSPERO (CRD42021234185).
RESULTS
We retrieved 6757 records and 12 COVID-19 pregnancy registries from the search strategy; 38 clinical and non-clinical studies (involving 2,398,855 pregnant persons and 56 pregnant animals) were included. Most studies (89%) were conducted in high-income countries and were cohort studies (57%). Most studies (76%) compared vaccine exposures with no exposure during the three trimesters of pregnancy. The most frequent exposure was to AS03 adjuvant, in the context of A/H1N1 pandemic influenza vaccines, (n = 24) and aluminum-based adjuvants (n = 11). Only one study reported exposure to messenger RNA in lipid nanoparticles COVID-19 vaccines. Except for one preliminary report about A/H1N1 influenza vaccination (adjuvant AS03), corrected by the authors in a more thorough analysis, all studies concluded that there were no safety concerns.
CONCLUSION
This rapid review found no evidence of pregnancy-associated safety concerns of COVID-19 vaccines or of their components or platforms when used in other vaccines. However, the need for further data on several vaccine platforms and components is warranted, given their novelty. Our findings support current WHO guidelines recommending that pregnant persons may consider receiving COVID-19 vaccines, particularly if they are at high risk of exposure or have comorbidities that enhance the risk of severe disease.

Identifiants

pubmed: 34489131
pii: S0264-410X(21)01067-7
doi: 10.1016/j.vaccine.2021.08.034
pmc: PMC8360993
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

5891-5908

Subventions

Organisme : Medical Research Council
ID : MR/R005990/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A900_1122
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R005990/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00026/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17221
Pays : United Kingdom

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Buekens Pierre M. reports financial support was provided by Bill & Melinda Gates Foundation.

Références

Milbank Q. 2021 Jun;99(2):426-449
pubmed: 33650737
NPJ Vaccines. 2019 Oct 18;4:44
pubmed: 31646004
Ann Intern Med. 2016 Dec 20;165(12):848-855
pubmed: 27654505
PLoS Med. 2021 Mar 29;18(3):e1003583
pubmed: 33780438
Vaccine. 2011 Feb 4;29(7):1357-8
pubmed: 21185422
Vaccine. 2018 Jan 2;36(1):50-54
pubmed: 29174107
Clin Infect Dis. 2015 Mar 1;60(5):e11-9
pubmed: 25409473
Vaccine. 2009 Sep 4;27(40):5530-7
pubmed: 19607950
BMJ. 2012 May 02;344:e2794
pubmed: 22551713
MMWR Morb Mortal Wkly Rep. 2020 Nov 06;69(44):1641-1647
pubmed: 33151921
BMJ. 2019 Mar 20;364:l869
pubmed: 30894356
PLoS One. 2012 Dec 20;7(12):e51734
pubmed: 23341865
JAMA. 2012 Jul 11;308(2):165-74
pubmed: 22782418
Obstet Gynecol. 2015 Nov;126(5):1075-1084
pubmed: 26444106
Drug Saf. 2013 Jun;36(6):455-65
pubmed: 23516007
Vaccine. 2018 Oct 1;36(41):6111-6116
pubmed: 30194002
Cochrane Database Syst Rev. 2018 Feb 01;2:CD001269
pubmed: 29388196
Int J Gynaecol Obstet. 2018 May;141(2):141-150
pubmed: 29149524
Clin Infect Dis. 2019 Jan 18;68(3):402-408
pubmed: 30475988
BMJ. 2015 Nov 16;351:h5585
pubmed: 26572546
Am J Obstet Gynecol. 2021 Sep;225(3):303.e1-303.e17
pubmed: 33775692
Vaccine. 2011 Nov 15;29(49):9159-70
pubmed: 21840359
J Perinat Med. 2020 Nov 26;48(9):900-911
pubmed: 33001856
Vaccine. 2011 Aug 26;29(37):6358-65
pubmed: 21596080
PLoS One. 2019 Aug 14;14(8):e0220910
pubmed: 31412058
CMAJ. 2014 Feb 4;186(2):137
pubmed: 24492526
J Travel Med. 2020 Mar 13;27(2):
pubmed: 31616947
Vaccine. 2012 Jun 22;30(30):4445-52
pubmed: 22564554
Rev Cubana Med Trop. 2011 Sep-Dec;63(3):231-8
pubmed: 23444612
Hum Vaccin Immunother. 2019;15(3):687-699
pubmed: 30380986
J Pediatr. 1964 Mar;64:357-71
pubmed: 14130709
J Pediatr. 1987 Apr;110(4):531-7
pubmed: 3559800
Vaccine. 2015 Sep 11;33(38):4850-7
pubmed: 26238723
N Engl J Med. 2021 Jun 17;384(24):2273-2282
pubmed: 33882218
Obstet Gynecol. 2021 Aug 1;138(2):278-280
pubmed: 33910219
Am J Obstet Gynecol. 2014 Jun;210(6):561.e1-6
pubmed: 24378675
Am J Perinatol. 2016 Sep;33(11):1104-14
pubmed: 27603545
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
J Clin Epidemiol. 2021 Feb;130:13-22
pubmed: 33068715
Pharmacoepidemiol Drug Saf. 2003 Jun;12(4):335-40
pubmed: 12812014
BJOG. 2012 Dec;119(13):1583-90
pubmed: 22901103
Vaccine. 2020 Sep 11;38(40):6215-6223
pubmed: 32741674
Am J Public Health. 2012 Jun;102(6):e33-40
pubmed: 22515877
N Engl J Med. 2020 Jul 30;383(5):426-439
pubmed: 32726529
BMJ. 2021 Jan 5;372:m4853
pubmed: 33402340
Lancet. 2021 Mar 13;397(10278):941
pubmed: 33714374
BMJ. 2020 Sep 1;370:m3320
pubmed: 32873575
Drug Saf. 2012 Jan 1;35(1):1-14
pubmed: 22149417
N Engl J Med. 1976 Jul 22;295(4):204-7
pubmed: 1272350
Vaccine. 2019 Oct 16;37(44):6648-6655
pubmed: 31548013
Br J Clin Pharmacol. 2012 May;73(5):801-11
pubmed: 22082196
Birth Defects Res. 2019 Nov 1;111(18):1420-1435
pubmed: 31580536
N Engl J Med. 2013 Jan 24;368(4):333-40
pubmed: 23323868
Vaccine. 2011 Feb 1;29(6):1180-4
pubmed: 21172382
Eur J Epidemiol. 2013 Jul;28(7):579-88
pubmed: 23715672
Acta Obstet Gynecol Scand. 2021 Jul;100(7):1200-1218
pubmed: 33560530
Vaccine. 2015 Nov 25;33(47):6488-92
pubmed: 26319066
Lancet. 2016 Oct 8;388(10053):1725-1774
pubmed: 27733285
PLoS One. 2021 Jun 29;16(6):e0253974
pubmed: 34185807
J Infect Dis. 2019 Oct 22;220(11):1802-1815
pubmed: 31402384
Clin Infect Dis. 2021 Nov 16;73(10):1909-1912
pubmed: 33822014
BJOG. 2015 Jan;122(1):17-26
pubmed: 25040307
BMJ. 2017 May 30;357:j2249
pubmed: 28559234

Auteurs

Agustín Ciapponi (A)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina. Electronic address: aciapponi@iecs.org.ar.

Ariel Bardach (A)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina. Electronic address: abardach@iecs.org.ar.

Agustina Mazzoni (A)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina. Electronic address: amazzoni@iecs.org.ar.

Tomás Alconada (T)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina.

Steven A Anderson (SA)

US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA. Electronic address: Steven.Anderson@fda.hhs.gov.

Fernando J Argento (FJ)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina. Electronic address: fargento@iecs.org.ar.

Jamile Ballivian (J)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina.

Karin Bok (K)

National Institute of Allergy and Infectious Diseases, National Institutes of Health, 31 Center Dr # 7A03, Bethesda, MD 20892, USA. Electronic address: karin.bok@nih.gov.

Daniel Comandé (D)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina. Electronic address: dcomande@iecs.org.ar.

Emily Erbelding (E)

National Institute of Allergy and Infectious Diseases, 1 Center Dr # 7A03, Bethesda, USA. Electronic address: emily.erbelding@nih.gov.

Erin Goucher (E)

School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St, New Orleans, LA 70112, USA. Electronic address: egoucher@tulane.edu.

Beate Kampmann (B)

The Vaccine Centre, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; Vaccines & Immunity Theme, MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, Gambia. Electronic address: Beate.Kampmann@lshtm.ac.uk.

Ruth Karron (R)

Bloomberg School of Public Health, Johns Hopkins University, 7CX5+8W Baltimore, MD, USA. Electronic address: rkarron@jhu.edu.

Flor M Munoz (FM)

Baylor College of Medicine, Texas Children's Hospital, 6621 Fannin St, Houston, TX 77030, USA. Electronic address: florm@bcm.edu.

María Carolina Palermo (MC)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina.

Edward P K Parker (EPK)

The Vaccine Centre, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK. Electronic address: Edward.Parker@lshtm.ac.uk.

Federico Rodriguez Cairoli (F)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina. Electronic address: fcairoli@iecs.org.ar.

Victoria Santa María (V)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina.

Andy S Stergachis (AS)

School of Pharmacy and School of Public Health, University of Washington, MM2R+78 Seattle, WA, USA. Electronic address: stergach@uw.edu.

Gerald Voss (G)

TuBerculosis Vaccine Initiative (TBVI), GHF4+6W Lelystad, the Netherlands. Electronic address: gerald.voss@cepi.net.

Xu Xiong (X)

School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St, New Orleans, LA 70112, USA. Electronic address: xxiong@tulane.edu.

Natalia Zamora (N)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina.

Sabra Zaraa (S)

School of Pharmacy, University of Washington, MM2R+78 Seattle, WA, USA. Electronic address: szaraa@uw.edu.

Mabel Berrueta (M)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Dr. Emilio Ravignani 2024 C1014CPV, Argentina. Electronic address: mberrueta@iecs.org.ar.

Pierre M Buekens (PM)

School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St, New Orleans, LA 70112, USA. Electronic address: pbuekens@tulane.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH